Prognostic re-evaluation of peritoneal lavage cytology in Japa...

Collect this paper and discover other ones on Labmeeting. Learn more.
- Hide Abstract
BACKGROUND/AIMS: The aim of the present study was to re-evaluate CY(+) with gastric carcinoma in Japanese patients to identify the characteristics that might distinguish patients with a poor prognosis from those with an intermediate prognosis among CY(+) patients. METHODOLOGY: CY(+) was found in 56 of 566 patients (9.9%) who had undergone surgery for gastric carcinoma between January 2000 and December 2006. The 56 patients with CY(+) were classified into four groups: group A, P(-)CY(+) (n = 10); group B, P1CY (+) (n = 10); group C, P2,3CY(+) (n = 18); group D, other (n = 18). RESULTS: The 5-year survival of all patients with CY(+) was 12%. A multivariate analysis demonstrated serosal invasion, lymph node metastasis, and CY(+) to be independent prognostic factors. However, the 5-year survival in group A was 30%. The prognosis of group A patients was significantly better than that of patients in any other group (Groups B, C, D; p < 0.02). Sites of the recurrence in group A were located only in the peritoneum but the lymph nodes, etc. CONCLUSIONS: Gastric carcinoma with CY(+) has a poor prognosis because it is associated with non-curative factors, peritoneal dissemination, and liver or lymph nodes metastases. However, a small subpopulation of patients with P(-)CY(+) showed an intermediate prognosis.
Hepato-gastroenterology 56(89):261-5, 2009Who cited this? | PubMed ID: 19453071 | Fulltext


+ Click Here for Related Papers


Join Labmeeting

  • Organize and search your PDF collection
  • Collect papers
  • Search millions of papers
  • Keep up to date with paper alerts
  • Read your papers from anywhere
  • Recommend papers to colleagues
  • Manage your lab

Join Labmeeting

Labmeeting is a web service for researchers. Sign up with your academic email address.

Individuals or corporations not affiliated with an academic institution can request a trial subscription.


Got a question?
The Labmeeting Network
has the answer.
Ask scientists at top universities like Harvard, Stanford, and MIT for their expert opinion!